Intellect Neurosciences (ILNS.OB) Completes Financial Restructuring, Highlights Expectations for Alzheimer’s Drug

In the company’s news yesterday,

Intellect Neurosciences Inc. announced that through the issuance of common stock, it was successful in extinguishing about $24 million of accrued interest of debt and preferred stock. In addition, the company said that several of its “significant” shareholders pooled together to provide enough funds fuel the company’s operations for the next 12 months. Company chairman and CEO Daniel Chain, PhD, said the funding enables the company to pursue new opportunities for its drug development.

“Our stakeholders recognize the value proposition inherent in Intellect’s intellectual property and pipeline programs,” Chain stated in the press release. “This financial restructuring is a tremendous accomplishment, opening up exciting new strategic opportunities to develop our internal drug development pipeline. We are pleased that our largest shareholders have provided us immediate financial resources to sustain our operations for the next 12 months and are committed to continue to support the company. The immediate cash infusion and our shareholders’ financial commitment should enable the company to maintain operations through completion of phase 3 trials for Bapineuzumab.”

Bapineuzumab, an antibody co-developed by Wyeth/Pfizer and Johnson & Johnson under a royalty-bearing license from Intellect, has the potential to be the first disease-modifying drug for AD on the market.

While currently marketed drugs are successful in transiently affecting some symptoms of AD, Intellect says there are no drugs available that slow or arrest the progression of the disease. However, Bapineuzumab has the potential to do so, and some analysts believe that Bapineuzumab may have the potential to reach several billion in annual worldwide sales.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.